Insights

The U.K. authorizes AstraZeneca’s coronavirus vaccine for emergency supply

The first authorization of its vaccine could be the only green light it receives for several months.
The post The U.K. authorizes AstraZeneca’s coronavirus vaccine for emergency supply appeared first on The Motley Fool Australia. –

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

On Wednesday morning, the U.K. authorized AstraZeneca‘s (NASDAQ: AZN) coronavirus vaccine candidate for emergency supply. The first doses of COVID-19 Vaccine AstraZeneca (formerly known as AZD1222) will be released today with the intention to begin vaccinations early in the new year.

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) recommends two full doses given four to 12 weeks apart. This is the dosing regimen that appeared 62% effective in clinical trials in the U.K. and Brazil.

You may remember an unintentionally administered half-dose/full-dose regimen that appeared more than 90% effective in a smaller group of patients. Unfortunately, data available to the MHRA wasn’t sufficient to persuade the agency to deviate from the two full doses received by the vast majority of clinical trial participants.

The European Medicines Agency (EMA) and the Food and Drug Administration aren’t on the same page as the MHRA. As a result, timelines for similar authorizations for AstraZeneca are still fuzzy. 

On Tuesday, EMA executive director Noel Wathion told reporters that AstraZeneca hasn’t even filed an application yet. While AstraZeneca has sent in some data, it hasn’t been enough to warrant a conditional marketing license.

In the U.S., COVID-19 Vaccine AstraZeneca’s path forward is going to be bumpy. The company’s CEO has hinted at more-compelling clinical trial data to come, but the results we’ve seen so far don’t meet the FDA’s pre-determined efficacy threshold. Plus, the FDA has clearly stated it’s unwilling to authorize a candidate without some pivotal data from a U.S. study. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post The U.K. authorizes AstraZeneca’s coronavirus vaccine for emergency supply appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!